Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
44
BNTC Quote, Financials, Valuation and Earnings
Last price:
$12.84
Seasonality move
:
8.41%
Day range:
$12.49 - $13.22
52-week range:
$9.49 - $17.15
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.77x
Volume:
483.2K
Avg. volume:
288.3K
1-year change:
33.81%
Market cap:
$446.3M
Revenue:
--
EPS (TTM):
-$1.01
Analysts' Opinion
-
Consensus RatingBenitec Biopharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.83, Benitec Biopharma, Inc. has an estimated upside of 96% from its current price of $13.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $13.18.
Fair Value
-
According to the consensus of 5 analysts, Benitec Biopharma, Inc. has 96% upside to fair value with a price target of $25.83 per share.
BNTC vs. S&P 500
-
Over the past 5 trading days, Benitec Biopharma, Inc. has overperformed the S&P 500 by 1.15% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Benitec Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Benitec Biopharma, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Benitec Biopharma, Inc. reported revenues of --.
Earnings Growth
-
Benitec Biopharma, Inc. has grown year-over-year earnings for 13 quarters straight. In the most recent quarter Benitec Biopharma, Inc. reported earnings per share of -$0.22.
Enterprise value:
352.5M
EV / Invested capital:
3.73x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-15.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$423K
Return On Assets:
-38.43%
Net Income Margin (TTM):
--
Return On Equity:
-40.23%
Return On Invested Capital:
-39.95%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $75K | -- | -- | -- | -- | |
| Gross Profit | -$164K | -$352K | -$423K | -$91K | -$118K | |
| Operating Income | -$20.5M | -$22.4M | -$38.4M | -$5.8M | -$9.8M | |
| EBITDA | -$20.2M | -$22.1M | -$38M | -$5.7M | -$9.7M | |
| Diluted EPS | -$11.60 | -$5.28 | -$1.01 | -$0.48 | -$0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16.4M | $17.1M | $26.4M | $68.3M | $95.1M | |
| Total Assets | $17.8M | $18.1M | $27.1M | $68.8M | $96M | |
| Current Liabilities | $1.6M | $3M | $4.5M | $4.6M | $2M | |
| Total Liabilities | $2.4M | $3.5M | $4.7M | $4.6M | $2.4M | |
| Total Equity | $15.5M | $14.6M | $22.3M | $64.2M | $93.6M | |
| Total Debt | $760K | $491K | $211K | -- | $403K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.4M | -$19.5M | -$22.1M | -$4.6M | -$3.4M | |
| Cash From Investing | -$1K | -$180K | -$17.8K | -- | -- | |
| Cash From Financing | $27.8M | $62.1M | $48.1M | $21.7M | -- | |
| Free Cash Flow | -$18.4M | -$19.7M | -$22.1M | -$4.6M | -$3.4M | |
BNTC
Sector
Market Cap
$446.3M
$28.8M
Price % of 52-Week High
76.85%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-13.09%
-1.32%
1-Year Price Total Return
33.81%
-20.64%
Beta (5-Year)
0.196
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$12.70
200-day SMA
Sell
Level
$13.57
Bollinger Bands (100)
Sell
Level
11.98 - 14.88
Chaikin Money Flow
Sell
Level
-7.9M
20-day SMA
Buy
Level
$12.94
Relative Strength Index (RSI14)
Sell
Level
47.47
ADX Line
Sell
Level
34.18
Williams %R
Neutral
Level
-31.9502
50-day SMA
Sell
Level
$14.24
MACD (12, 26)
Sell
Level
-0.52
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
56.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (76.7996)
Sell
CA Score
(Annual)
Level (-0.8704)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (28.1869)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.
Stock Forecast FAQ
In the current month, BNTC has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BNTC average analyst price target in the past 3 months is $25.83.
-
Where Will Benitec Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Benitec Biopharma, Inc. share price will rise to $25.83 per share over the next 12 months.
-
What Do Analysts Say About Benitec Biopharma, Inc.?
Analysts are divided on their view about Benitec Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Benitec Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Benitec Biopharma, Inc.'s Price Target?
The price target for Benitec Biopharma, Inc. over the next 1-year time period is forecast to be $25.83 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BNTC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Benitec Biopharma, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BNTC?
You can purchase shares of Benitec Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Benitec Biopharma, Inc. shares.
-
What Is The Benitec Biopharma, Inc. Share Price Today?
Benitec Biopharma, Inc. was last trading at $12.84 per share. This represents the most recent stock quote for Benitec Biopharma, Inc.. Yesterday, Benitec Biopharma, Inc. closed at $13.18 per share.
-
How To Buy Benitec Biopharma, Inc. Stock Online?
In order to purchase Benitec Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BNTC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BNTC
Sector
P/E ratio
--
23.71x
PEG ratio
--
-0.01x
P/B ratio
4.77x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
BNTC
Sector
Revenue growth
--
4.85%
Earnings growth
54.58%
11.15%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$0.42
-$0.20
Profitability
BNTC
Sector
Profitability FY 2025
-$396K
$3.6M
Return on invested capital
-39.95%
-30.98%
Return on assets
-38.43%
-27.62%
Return on equity
-40.23%
-36.69%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Feb
13
Balance Sheet
BNTC
Sector
Total cash
$94.6M
$27.2M
Short term investments
--
$25.7M
Total assets
$99.6M
$79.7M
Long term debt
$403K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 95.04% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 0.04% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 2.16% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
